Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 13/20 | 0.79 |
| ▸ | JAK1 | P23458 | 8/20 | 0.73 |
| ▸ | JAK3 | P52333 | 8/20 | 0.68 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.68 |
| ▸ | IKBKB | O14920 | 1/20 | 0.57 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | TYK2 | P29597 | 1/20 | 0.57 |
| ▸ | SYK | P43405 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1422593 | 0.92 | JAK2 (0.76) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL3205999 | 0.90 | JAK2 (0.64) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL3655773 | 0.89 | JAK2 (0.84) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL3210951 | 0.89 | JAK2 (0.61) | JAK2JAK1JAK3PTK2 | |
| SCHEMBL7977771 | 0.89 | JAK2 (0.84) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL3213555 | 0.89 | JAK2 (1.00) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL3192928 | 0.88 | JAK2 (0.62) | JAK2JAK1JAK3PTK2 | |
| SCHEMBL16250512 | 0.88 | JAK2 (0.62) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL7977780 | 0.88 | JAK2 (0.82) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL3215845 | 0.88 | JAK2 (0.60) | JAK2JAK1JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378449-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378449-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| WO-2010010188-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378449-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.